An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) will host a live webcast to report Q4 and full year 2023 financial results and provide a corporate update, focusing on revolutionizing treatment for patients starting with eye care.
Positive
None.
Negative
None.
IRVINE, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it will host a live webcast at 5 a.m. PT / 8 a.m. ET on Tuesday, February 27, 2024 to report its fourth quarter and full year 2023 financial results and provide a corporate update.
Participants may access the webcast here. A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for at least 90 days.
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. XDEMVY (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-03 as an investigational therapy for the treatment of Meibomian Gland Disease, TP-04 for the potential treatment of rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease, all of which are in Phase 2.
Media Contact:
Adrienne Kemp
Sr. Director, Corporate Communications
(949) 922-0801
AKemp@tarsusrx.com
Investor Contact:
David Nakasone
Head of Investor Relations
(949) 620-3223
DNakasone@tarsusrx.com
FAQ
When will Tarsus Pharmaceuticals host the live webcast to report its financial results?
Tarsus Pharmaceuticals will host the live webcast at 5 a.m. PT / 8 a.m. ET on Tuesday, February 27, 2024.
What is the ticker symbol for Tarsus Pharmaceuticals?
The ticker symbol for Tarsus Pharmaceuticals is TARS.
What is the focus area of Tarsus Pharmaceuticals?
Tarsus Pharmaceuticals focuses on unmet needs and applies proven science and new technology to revolutionize treatment for patients, starting with eye care.
Where can participants access the webcast hosted by Tarsus Pharmaceuticals?
Participants can access the webcast on the Tarsus Pharmaceuticals website.
How long will the recorded version of the call be available on the website?
The recorded version of the call will be available on the website for at least 90 days after the completion of the webcast.
tarsus pharmaceuticals, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. its lead product candidate is tp-03, a novel therapeutic that is in phase iib/iii for the treatment of blepharitis caused by the infestation of demodex mites, as well as to treat meibomian gland disease. the company is also developing tp-04 for the treatment of rosacea; and tp-05 for lyme prophylaxis and community malaria reduction. tarsus pharmaceuticals, inc. was founded in 2016 and is headquartered in irvine, california.
